Melasma-like facial hyperpigmentation associated with long-term dasatinib therapy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a rare cutaneous adverse event
Tyrosine kinase inhibitors (TKIs) have significantly improved survival in Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib, a second-generation TKI, is frequently used in Ph+ ALL due to its potent BCR-ABL inh...